MoonLake Immunotherapeutics (MLTX) Operating Leases (2022 - 2026)

MoonLake Immunotherapeutics' Operating Leases history runs 5 years deep, the most recent figure standing at $1.8 million for Q1 2026.

• On a quarterly basis, Operating Leases rose 56.3% year-over-year to $1.8 million in Q1 2026; TTM through Mar 2026 was $1.8 million, a 56.3% increase from a year earlier, with the FY2025 full-year figure at $374000.0, down 74.35% from the prior year.
• Operating Leases rose to $1.8 million in Q1 2026 per MLTX's latest filing, from $374000.0 in the prior quarter.
• Across five years, Operating Leases topped out at $3.7 million in Q1 2024 and bottomed at $13084.0 in Q3 2023.
• The 5-year median for Operating Leases is $1.3 million (2024), against an average of $1.4 million.
• Across the five-year window, Operating Leases jumped 14694.47% in 2024 and slumped 74.89% in 2025, its largest moves.
• Year by year, Operating Leases stood at $128951.0 in 2022, then surged by 1838.71% to $2.5 million in 2023, then sank by 41.68% to $1.5 million in 2024, then plunged by 74.35% to $374000.0 in 2025, then jumped by 377.27% to $1.8 million in 2026.
• Per Business Quant, the three latest MLTX Operating Leases figures stand at $1.8 million (Q1 2026), $374000.0 (Q4 2025), and $486000.0 (Q3 2025).